I have had the privilege to partner with Novartis and Incyte on the RUXCOVID study, a study of ruxolitinib for COVID-19. The results released today did not provide evidence to support the use of ruxolitinib for patients with severe COVID-19.
While we are all disappointed, this is why we do randomized, controlled trials. Without them, we have no objectivity and no ability to establish ground truth amidst this storm we have found ourselves in. While I wish we had found something that could help with this horrible disease, I am so proud of the dedicated efforts put in by investigators worldwide as well as the Novartis and Incyte teams.
I am also proud of the integrity with which the study was conducted and the watchful care we were able to provide for the patients we treated.
To read more about this interesting study, please click here: https://www.novartis.com/news/media-releases/novartis-provides-update-ruxcovid-study-ruxolitinib-hospitalized-patients-covid-19